Published in J Clin Immunol on September 02, 2011
Ex vivo expansion of human mesenchymal stem cells in defined serum-free media. Stem Cells Int (2012) 1.20
Platelet lysate as replacement for fetal bovine serum in mesenchymal stromal cell cultures. Transfus Med Hemother (2013) 1.08
Optimization of human mesenchymal stem cell manufacturing: the effects of animal/xeno-free media. Sci Rep (2015) 0.89
Partnership between platelet-rich plasma and mesenchymal stem cells: in vitro experience. Muscles Ligaments Tendons J (2014) 0.87
Functional and differential proteomic analyses to identify platelet derived factors affecting ex vivo expansion of mesenchymal stromal cells. BMC Cell Biol (2013) 0.87
A robust potency assay highlights significant donor variation of human mesenchymal stem/progenitor cell immune modulatory capacity and extended radio-resistance. Stem Cell Res Ther (2015) 0.84
Platelet lysate as a substitute for animal serum for the ex-vivo expansion of mesenchymal stem/stromal cells: present and future. Stem Cell Res Ther (2016) 0.84
Advancing biomaterials of human origin for tissue engineering. Prog Polym Sci (2015) 0.81
A therapy-grade protocol for differentiation of pluripotent stem cells into mesenchymal stem cells using platelet lysate as supplement. Stem Cell Res Ther (2015) 0.80
Human Platelet Lysate as a Xeno Free Alternative of Fetal Bovine Serum for the In Vitro Expansion of Human Mesenchymal Stromal Cells. Int J Hematol Oncol Stem Cell Res (2016) 0.75
Safety of Intraperitoneal Injection of Adipose Tissue-Derived Autologous Mesenchymal Stem Cells in Cats. J Vet Intern Med (2015) 0.75
The production method affects the efficacy of platelet derivatives to expand mesenchymal stromal cells in vitro. J Transl Med (2017) 0.75
Human Bone Marrow Mesenchymal Stem/Stromal Cells Preserve Their Immunomodulatory and Chemotactic Properties When Expanded in a Human Plasma Derived Xeno-Free Medium. Stem Cells Int (2017) 0.75
Multilineage potential of adult human mesenchymal stem cells. Science (1999) 66.19
Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy (2006) 37.55
Human mesenchymal stem cells modulate allogeneic immune cell responses. Blood (2004) 13.79
Sensitive and viable identification of antigen-specific CD8+ T cells by a flow cytometric assay for degranulation. J Immunol Methods (2003) 11.81
Mesenchymal stem cells reside in virtually all post-natal organs and tissues. J Cell Sci (2006) 8.09
Growth factors and cytokines in wound healing. Wound Repair Regen (2009) 7.14
Mesenchymal stem cells suppress lymphocyte proliferation in vitro and prolong skin graft survival in vivo. Exp Hematol (2002) 6.92
Mesenchymal stem cells for treatment of therapy-resistant graft-versus-host disease. Transplantation (2006) 5.33
Mesenchymal stem cells inhibit and stimulate mixed lymphocyte cultures and mitogenic responses independently of the major histocompatibility complex. Scand J Immunol (2003) 4.62
IL-2 regulates FOXP3 expression in human CD4+CD25+ regulatory T cells through a STAT-dependent mechanism and induces the expansion of these cells in vivo. Blood (2006) 4.46
Human mesenchymal stem cells alter antigen-presenting cell maturation and induce T-cell unresponsiveness. Blood (2004) 4.04
Analysing cell division in vivo and in vitro using flow cytometric measurement of CFSE dye dilution. J Immunol Methods (2000) 3.89
Precursors for fibroblasts in different populations of hematopoietic cells as detected by the in vitro colony assay method. Exp Hematol (1974) 3.75
Interactions between human mesenchymal stem cells and natural killer cells. Stem Cells (2005) 3.36
Cotransplantation of HLA-identical sibling culture-expanded mesenchymal stem cells and hematopoietic stem cells in hematologic malignancy patients. Biol Blood Marrow Transplant (2005) 2.82
Clinical responses to bone marrow transplantation in children with severe osteogenesis imperfecta. Blood (2001) 2.65
Mesenchymal stem cells effectively modulate pathogenic immune response in experimental autoimmune encephalomyelitis. Ann Neurol (2007) 2.64
Mesenchymal stem cells inhibit the formation of cytotoxic T lymphocytes, but not activated cytotoxic T lymphocytes or natural killer cells. Transplantation (2003) 2.49
Internalized antigens must be removed to prepare hypoimmunogenic mesenchymal stem cells for cell and gene therapy. Mol Ther (2004) 2.35
In vitro expansion of human mesenchymal stem cells: choice of serum is a determinant of cell proliferation, differentiation, gene expression, and transcriptome stability. Stem Cells (2005) 2.33
Immunomodulatory effects of fetal and adult mesenchymal stem cells. Cytotherapy (2003) 2.28
Platelet lysates promote mesenchymal stem cell expansion: a safety substitute for animal serum in cell-based therapy applications. J Cell Physiol (2005) 2.26
Veto-like activity of mesenchymal stem cells: functional discrimination between cellular responses to alloantigens and recall antigens. J Immunol (2003) 2.21
Human platelet lysate can replace fetal bovine serum for clinical-scale expansion of functional mesenchymal stromal cells. Transfusion (2007) 2.20
Human alternatives to fetal bovine serum for the expansion of mesenchymal stromal cells from bone marrow. Stem Cells (2009) 2.19
Inflammatory cytokine-induced intercellular adhesion molecule-1 and vascular cell adhesion molecule-1 in mesenchymal stem cells are critical for immunosuppression. J Immunol (2010) 2.12
Rapid large-scale expansion of functional mesenchymal stem cells from unmanipulated bone marrow without animal serum. Tissue Eng Part C Methods (2008) 1.73
Animal serum-free culture conditions for isolation and expansion of multipotent mesenchymal stromal cells from human BM. Cytotherapy (2006) 1.64
Treatment of refractory acute GVHD with third-party MSC expanded in platelet lysate-containing medium. Bone Marrow Transplant (2008) 1.61
Human mesenchymal stem cells and cyclosporin a exert a synergistic suppressive effect on in vitro activation of alloantigen-specific cytotoxic lymphocytes. Biol Blood Marrow Transplant (2005) 1.58
Bone marrow-derived mesenchymal stem cells ameliorate autoimmune enteropathy independently of regulatory T cells. Stem Cells (2008) 1.58
Optimization of in vitro expansion of human multipotent mesenchymal stromal cells for cell-therapy approaches: further insights in the search for a fetal calf serum substitute. J Cell Physiol (2007) 1.57
Humanized system to propagate cord blood-derived multipotent mesenchymal stromal cells for clinical application. Regen Med (2007) 1.57
Platelets and wound healing. Front Biosci (2008) 1.56
Cytomegalovirus in transplantation - challenging the status quo. Clin Transplant (2007) 1.43
Accelerated and safe expansion of human mesenchymal stromal cells in animal serum-free medium for transplantation and regenerative medicine. J Cell Physiol (2007) 1.42
New approach to radiation burn treatment by dosimetry-guided surgery combined with autologous mesenchymal stem cell therapy. Regen Med (2007) 1.39
Mesenchymal stem cells in hematopoietic stem cell transplantation. Cytotherapy (2009) 1.35
The immunosuppressive effects of human bone marrow-derived mesenchymal stem cells target T cell proliferation but not its effector function. Cell Immunol (2008) 1.29
Mesenchymal stem cells exert differential effects on alloantigen and virus-specific T-cell responses. Blood (2008) 1.23
Two steps to functional mesenchymal stromal cells for clinical application. Transfusion (2007) 1.23
Donor-derived mesenchymal stem cells suppress alloreactivity of kidney transplant patients. Transplantation (2009) 1.22
Transplantation of mesenchymal stem cells attenuates myocardial injury and dysfunction in a rat model of acute myocarditis. J Mol Cell Cardiol (2006) 1.22
Human platelet lysate allows expansion and clinical grade production of mesenchymal stromal cells from small samples of bone marrow aspirates or marrow filter washouts. Bone Marrow Transplant (2007) 1.19
Ex vivo expansion of mesenchymal stromal cells. Best Pract Res Clin Haematol (2011) 1.18
Toward MSC in solid organ transplantation: 2008 position paper of the MISOT study group. Transplantation (2009) 1.16
Human adipose tissue-derived mesenchymal stem cells induce explosive T-cell proliferation. Stem Cells Dev (2010) 1.16
Immunomodulatory effect of mesenchymal stromal cells: possible mechanisms. Regen Med (2008) 1.16
Fetal bovine serum: a multivariate standard. Proc Soc Exp Biol Med (1975) 1.15
Platelet-rich plasma improves expansion of human mesenchymal stem cells and retains differentiation capacity and in vivo bone formation in calcium phosphate ceramics. Platelets (2006) 1.14
Preparation of pooled human platelet lysate (pHPL) as an efficient supplement for animal serum-free human stem cell cultures. J Vis Exp (2009) 1.10
From bone marrow to therapeutic applications: different behaviour and genetic/epigenetic stability during mesenchymal stem cell expansion in autologous and foetal bovine sera? Int J Dev Biol (2008) 1.08
Potential of mesenchymal stem cells as immune therapy in solid-organ transplantation. Transpl Int (2008) 1.06
A paradoxical role for IFN-gamma in the immune properties of mesenchymal stem cells during viral challenge. Exp Hematol (2005) 0.97
Human mesenchymal stem cells suppress induction of cytotoxic response to alloantigens. Biorheology (2004) 0.95
Differential immunomodulatory effects of fetal versus maternal multipotent stromal cells. Hum Immunol (2008) 0.95
Comparison of ex vivo expansion culture conditions of mesenchymal stem cells for human cell therapy. Transfusion (2009) 0.94
Therapeutic potential of bone marrow stem cells for liver diseases. Curr Stem Cell Res Ther (2006) 0.92
Cell culture medium composition and translational adult bone marrow-derived stem cell research. Stem Cells (2006) 0.92
Sensitive balance of suppressing and activating effects of mesenchymal stem cells on T-cell proliferation. Transplantation (2006) 0.90
Intravenous transplantation of mesenchymal stem cells improves cardiac performance after acute myocardial ischemia in female rats. Transpl Int (2006) 0.85
Stem cells and cardiac regeneration. Transpl Int (2007) 0.85
Elucidating the contribution of the elemental composition of fetal calf serum to antigenic expression of primary human umbilical-vein endothelial cells in vitro. Biosci Rep (2011) 0.79
Granulocyte-macrophage colony-stimulating factor to reverse sepsis-associated immunosuppression: a double-blind, randomized, placebo-controlled multicenter trial. Am J Respir Crit Care Med (2009) 4.98
IL-22 regulates the expression of genes responsible for antimicrobial defense, cellular differentiation, and mobility in keratinocytes: a potential role in psoriasis. Eur J Immunol (2006) 4.88
Stroke-induced immunodeficiency promotes spontaneous bacterial infections and is mediated by sympathetic activation reversal by poststroke T helper cell type 1-like immunostimulation. J Exp Med (2003) 3.89
Development of a cross-platform biomarker signature to detect renal transplant tolerance in humans. J Clin Invest (2010) 3.41
The lymphocyte transformation test for borrelia detects active lyme borreliosis and verifies effective antibiotic treatment. Open Neurol J (2012) 2.99
The effect of micronutrient supplementation on quality-of-life and left ventricular function in elderly patients with chronic heart failure. Eur Heart J (2005) 2.92
Effect of immunisation against angiotensin II with CYT006-AngQb on ambulatory blood pressure: a double-blind, randomised, placebo-controlled phase IIa study. Lancet (2008) 2.77
MK2 targets AU-rich elements and regulates biosynthesis of tumor necrosis factor and interleukin-6 independently at different post-transcriptional levels. J Biol Chem (2001) 2.76
A circadian clock in macrophages controls inflammatory immune responses. Proc Natl Acad Sci U S A (2009) 2.71
Different faces of the heme-heme oxygenase system in inflammation. Pharmacol Rev (2003) 2.52
Immunologic and hemodynamic effects of "low-dose" hydrocortisone in septic shock: a double-blind, randomized, placebo-controlled, crossover study. Am J Respir Crit Care Med (2002) 2.52
Terminally differentiated CD8⁺ T cells negatively affect bone regeneration in humans. Sci Transl Med (2013) 2.43
Preventive antibacterial therapy in acute ischemic stroke: a randomized controlled trial. PLoS One (2008) 2.39
Cytomegalovirus (CMV) phosphoprotein 65 makes a large contribution to shaping the T cell repertoire in CMV-exposed individuals. J Infect Dis (2002) 2.33
Protection from cytomegalovirus after transplantation is correlated with immediate early 1-specific CD8 T cells. J Exp Med (2005) 2.28
Human platelet lysate can replace fetal bovine serum for clinical-scale expansion of functional mesenchymal stromal cells. Transfusion (2007) 2.20
Human alternatives to fetal bovine serum for the expansion of mesenchymal stromal cells from bone marrow. Stem Cells (2009) 2.19
Ursodeoxycholic acid in patients with chronic heart failure: a double-blind, randomized, placebo-controlled, crossover trial. J Am Coll Cardiol (2012) 2.11
Regulatory T cells induce a privileged tolerant microenvironment at the fetal-maternal interface. Eur J Immunol (2006) 2.04
Humanized large-scale expanded endothelial colony-forming cells function in vitro and in vivo. Blood (2009) 2.00
The activation status of neuroantigen-specific T cells in the target organ determines the clinical outcome of autoimmune encephalomyelitis. J Exp Med (2004) 1.90
IL-22 induces lipopolysaccharide-binding protein in hepatocytes: a potential systemic role of IL-22 in Crohn's disease. J Immunol (2007) 1.80
Blood monocytes mimic endothelial progenitor cells. Stem Cells (2005) 1.79
IL-22 and IL-20 are key mediators of the epidermal alterations in psoriasis while IL-17 and IFN-gamma are not. J Mol Med (Berl) (2009) 1.76
Naturally occurring anti-IFN-gamma autoantibody and severe infections with Mycobacterium cheloneae and Burkholderia cocovenenans. Blood (2003) 1.76
Abnormal T-cell reactivity against paternal antigens in spontaneous abortion: adoptive transfer of pregnancy-induced CD4+CD25+ T regulatory cells prevents fetal rejection in a murine abortion model. Am J Pathol (2005) 1.74
Monitoring temporary immunodepression by flow cytometric measurement of monocytic HLA-DR expression: a multicenter standardized study. Clin Chem (2005) 1.74
Rapid large-scale expansion of functional mesenchymal stem cells from unmanipulated bone marrow without animal serum. Tissue Eng Part C Methods (2008) 1.73
Random screening of proteins for HLA-A*0201-binding nine-amino acid peptides is not sufficient for identifying CD8 T cell epitopes recognized in the context of HLA-A*0201. J Immunol (2004) 1.68
A vaccine for hypertension based on virus-like particles: preclinical efficacy and phase I safety and immunogenicity. J Hypertens (2007) 1.68
Immune cells mimic the morphology of endothelial progenitor colonies in vitro. Stem Cells (2007) 1.66
Ex vivo exposure to carbon monoxide prevents hepatic ischemia/reperfusion injury through p38 MAP kinase pathway. Hepatology (2002) 1.62
Tuberculin-specific T cells are reduced in active pulmonary tuberculosis compared to LTBI or status post BCG vaccination. J Infect Dis (2010) 1.58
Humanized system to propagate cord blood-derived multipotent mesenchymal stromal cells for clinical application. Regen Med (2007) 1.57
Prospective assessment of antidonor cellular alloreactivity is a tool for guidance of immunosuppression in kidney transplantation. Kidney Int (2013) 1.54
Immune privilege of endothelial cells differentiated from endothelial progenitor cells. Cardiovasc Res (2010) 1.53
Heme oxygenase-1 and its reaction product, carbon monoxide, prevent inflammation-related apoptotic liver damage in mice. Hepatology (2003) 1.52
Altered intestinal function in patients with chronic heart failure. J Am Coll Cardiol (2007) 1.48
Low immunogenicity of endothelial derivatives from rat embryonic stem cell-like cells. Cell Res (2009) 1.46
Increased indoleamine 2,3-dioxygenase (IDO) activity and elevated serum levels of tryptophan catabolites in patients with chronic kidney disease: a possible link between chronic inflammation and uraemic symptoms. Nephrol Dial Transplant (2009) 1.44
Immunopathogenesis of psoriasis. Exp Dermatol (2007) 1.44
The dying stem cell hypothesis: immune modulation as a novel mechanism for progenitor cell therapy in cardiac muscle. J Am Coll Cardiol (2005) 1.43
Cellular immunodepression preceding infectious complications after acute ischemic stroke in humans. Cerebrovasc Dis (2007) 1.42
Interleukin (IL)-19, IL-20 and IL-24 are produced by and act on keratinocytes and are distinct from classical ILs. Exp Dermatol (2006) 1.41
Autologous Epstein-Barr virus (EBV)-specific cytotoxic T cells for the treatment of persistent active EBV infection. Blood (2002) 1.40
Loss of receptor on tuberculin-reactive T-cells marks active pulmonary tuberculosis. PLoS One (2007) 1.39
Human dermis harbors distinct mesenchymal stromal cell subsets. J Invest Dermatol (2011) 1.37
Immunogenicity and immunomodulatory properties of umbilical cord lining mesenchymal stem cells. Cell Transplant (2010) 1.36
How to track cellular aging of mesenchymal stromal cells? Aging (Albany NY) (2010) 1.34
TNF-related apoptosis inducing ligand (TRAIL) as a potential response marker for interferon-beta treatment in multiple sclerosis. Lancet (2003) 1.30
Reciprocal leukemia-stroma VCAM-1/VLA-4-dependent activation of NF-κB mediates chemoresistance. Blood (2014) 1.29
Human chorionic gonadotropin attracts regulatory T cells into the fetal-maternal interface during early human pregnancy. J Immunol (2009) 1.28
Mapping T cell epitopes by flow cytometry. Methods (2003) 1.27
Oral high-dose atorvastatin treatment in relapsing-remitting multiple sclerosis. PLoS One (2008) 1.27
Standardization of whole blood immune phenotype monitoring for clinical trials: panels and methods from the ONE study. Transplant Res (2013) 1.27
Maturing dendritic cells are an important source of IL-29 and IL-20 that may cooperatively increase the innate immunity of keratinocytes. J Leukoc Biol (2008) 1.26
Elimination of protein kinase MK5/PRAK activity by targeted homologous recombination. Mol Cell Biol (2003) 1.26
Cutting Edge: Immunological consequences and trafficking of human regulatory macrophages administered to renal transplant recipients. J Immunol (2011) 1.25
Enzyme-linked immunosorbent spot assay for donor-reactive interferon-gamma-producing cells identifies T-cell presensitization and correlates with graft function at 6 and 12 months in renal-transplant recipients. Transplantation (2004) 1.25
Human extramedullary bone marrow in mice: a novel in vivo model of genetically controlled hematopoietic microenvironment. Blood (2012) 1.25
Heme oxygenase-1 gene transfer inhibits inducible nitric oxide synthase expression and protects genetically fat Zucker rat livers from ischemia-reperfusion injury. Transplantation (2002) 1.24
Analysis of antigen-specific T-cell responses with synthetic peptides--what kind of peptide for which purpose? Hum Immunol (2004) 1.24
Two steps to functional mesenchymal stromal cells for clinical application. Transfusion (2007) 1.23
Heme oxygenase-1 inhibits rat and human breast cancer cell proliferation: mutual cross inhibition with indoleamine 2,3-dioxygenase. FASEB J (2005) 1.21
Preventive antibacterial treatment improves the general medical and neurological outcome in a mouse model of stroke. Stroke (2003) 1.21
The Th17 cytokine IL-22 induces IL-20 production in keratinocytes: a novel immunological cascade with potential relevance in psoriasis. Eur J Immunol (2009) 1.19
Early IL-6 plasma concentrations correlate with severity of brain injury and pneumonia in brain-injured patients. J Trauma (2002) 1.18
Identification of dialysis patients with panel-reactive memory T cells before kidney transplantation using an allogeneic cell bank. J Am Soc Nephrol (2006) 1.18
Evidence for the pivotal role of endogenous toll-like receptor 4 ligands in liver ischemia and reperfusion injury. Transplantation (2008) 1.17
Toward MSC in solid organ transplantation: 2008 position paper of the MISOT study group. Transplantation (2009) 1.16
Phenotype changes and impaired function of dendritic cell subsets in patients with sepsis: a prospective observational analysis. Crit Care (2009) 1.16
Consider delayed immunosuppression into the concept of sepsis. Crit Care Med (2008) 1.16
Replicative senescence-associated gene expression changes in mesenchymal stromal cells are similar under different culture conditions. Haematologica (2010) 1.14
Elevated circulating levels of inflammatory cytokines and bacterial endotoxin in adults with congenital heart disease. Am J Cardiol (2003) 1.12
Heat shock protein 70 in patients with chronic heart failure: relation to disease severity and survival. Int J Cardiol (2004) 1.11
Heme oxygenase 1 gene transfer prevents CD95/Fas ligand-mediated apoptosis and improves liver allograft survival via carbon monoxide signaling pathway. Hum Gene Ther (2002) 1.11
Preparation of pooled human platelet lysate (pHPL) as an efficient supplement for animal serum-free human stem cell cultures. J Vis Exp (2009) 1.10
High levels of CMV-IE-1-specific memory T cells are associated with less alloimmunity and improved renal allograft function. Transpl Immunol (2008) 1.10
IL-10 interferes directly with TCR-induced IFN-gamma but not IL-17 production in memory T cells. Eur J Immunol (2009) 1.09
IL-29 is produced by T(H)17 cells and mediates the cutaneous antiviral competence in psoriasis. Sci Transl Med (2013) 1.09
Studies on bacterial endotoxin and intestinal absorption function in patients with chronic heart failure. Int J Cardiol (2010) 1.09
CMV-specific central memory T cells reside in bone marrow. Eur J Immunol (2007) 1.08
Pre-eclampsia is not associated with changes in the levels of regulatory T cells in peripheral blood. Am J Reprod Immunol (2005) 1.08
Immune responses after acute ischemic stroke or myocardial infarction. Int J Cardiol (2010) 1.08
Clinical Protocols for the Isolation and Expansion of Mesenchymal Stromal Cells. Transfus Med Hemother (2008) 1.07
Advancement of mesenchymal stem cell therapy in solid organ transplantation (MISOT). Transplantation (2010) 1.07
Enhanced granulysin mRNA expression in urinary sediment in early and delayed acute renal allograft rejection. Transplantation (2004) 1.07
Multiple mechanisms of reduced major histocompatibility complex class II expression in endotoxin tolerance. J Biol Chem (2003) 1.06
Probiotic therapy in the prevention of pouchitis onset: decreased interleukin-1beta, interleukin-8, and interferon-gamma gene expression. Inflamm Bowel Dis (2005) 1.06
Inhibition of ischemia/reperfusion injury and chronic graft deterioration by a single-donor treatment with cobalt-protoporphyrin for the induction of heme oxygenase-1. Transplantation (2002) 1.05